目的 探讨龙鹿丸联合重组人促卵泡激素治多囊卵巢综合征不孕症的临床疗效。方法 选择2017年3月—2018年6月在郑州大学第二附属医院妇科门诊进行治疗的80例多囊卵巢综合征不孕症患者，随机分为对照组和治疗组，每组各40例。对照组患者在月经前7 d内皮下注射注射用重组人促卵泡激素，75 U/次，1次/d，用药期间行超声监测，适时调整剂量至卵泡成熟后，给予人绒毛膜促性腺激素（hCG）1万单位诱发排卵，指导患者同房。若有多卵泡发育，则取消扳机和试孕。治疗组在对照组治疗基础上口服龙鹿丸，1 g/次，3次/d。两组均连续治疗3～6个周期。观察两组的临床疗效，比较两组彩超指标、血清学指标、性激素水平的变化情况。比较两组排卵率和妊娠率。结果 治疗后，对照组和治疗组的总有效率分别是80.00%、97.50%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者子宫内膜厚度、优势卵泡数量均较治疗前显著增高，而卵巢体积显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组子宫内膜厚度、优势卵泡数量显著高于对照组，而卵巢体积显著小于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清游离脂肪酸（FFA）、干细胞生长因子（HGF）、血管内皮生长因子（VEGF）水平均较治疗前显著下降，而性激素结合球蛋白（SHBG）、β-促脂激素C末端31肽（β-EP）水平均显著增高，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组FFA、HGF、VEGF水平显著低于对照组，而SHBG、β-EP水平高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组孕酮（P）、雌二醇（E₂）、促卵泡激素（FSH）水平均较治疗前显著增高，而睾酮（T）、黄体生成素（LH）水平均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组P、E₂、FSH水平显著高于对照组，而T、LH水平低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，对照组排卵率、妊娠率分别是37.5%、12.5%；治疗组排卵率、妊娠率分别是62.5%、32.5%，两组排卵率、妊娠率比较差异具有统计学意义（P<0.05）。结论 龙鹿丸联合重组人促卵泡激素治疗多囊卵巢综合征不孕症效果显著，可有效改善机体性激素水平，调节机体相关血清学指标水平，促进排卵功能，提高妊娠率，具有一定的临床推广应用价值。

Objective To explore the clinical efficacy of Longlu Pills combined with recombinant human follitropin in treatment of polycystic ovary syndrome with infertility. Methods Patients (80 cases) with polycystic ovary syndrome with infertility in department of gynaecology of the Second Affiliated Hospital of Zhengzhou University from March 2017 to June 2018 were randomly divided into treatment group (40 cases) and control group (40 cases). Patients in the control group were sc administered with Recombinant Human Follitropin for injection within 7 d before menstruation, 75 U/time, once daily. Ultrasonic monitoring was conducted during the medication, and the dosage was adjusted timely until the follicle was mature. Ten thousand units of human chorionic gonadotropin (hCG) were given to induce ovulation and guide patients to have sex. If multiple follicles develop, the trigger and pregnancy test were cancelled. Patients in the treatment group were po administered with Longlu Pills, 1 g/time, three times daily. Patients in two groups were treated for 3 - 6 cycles. After treatment, the clinical efficacy was evaluated, and the changes of color doppler ultrasound indexes, serological indexes and sex hormone levels in two groups were compared. Ovulation rate and pregnancy rate were compared between the two groups. Results After treatment, the clinical efficacy in the control and treatment groups were 80.00% and 97.50%, respectively, and there were differences between two groups (P<0.05). After treatment, endometrial thickness, numbers of dominant follicles in two groups were significantly increased, but ovarian volume was significantly decreased, and there were differences in the same group (P<0.05). After treatment, endometrial thickness, numbers of dominant follicles in the treatment group were higher than those in the control group, but ovarian volume was lower than those in the control group, and there were differences between two groups (P<0.05). After treatment, FFA, HGF, and VEGF in two groups were significantly decreased, but SHBG and β-EP were significantly increased, and there were differences in the same group (P<0.05). After treatment, FFA, HGF, and VEGF in the treatment group were lower than those in the control group, but SHBG and β-EP were higher than those in the control group, and there were differences between two groups (P<0.05). After treatment, P, E₂, and FSH in two groups were significantly increased, but T and LH was significantly decreased, and there were differences in the same group (P<0.05). After treatment, P, E₂, and FSH in the treatment group were higher than those in the control group, but T and LH were lower than those in the control group, and there were differences between two groups (P<0.05). After treatment, the ovulation rate and pregnancy rate in the control group were 37.5% and 12.5%, respectively, and ovulation rate and pregnancy rate in the treatment group were 62.5% and 32.5%, and there were differences between two groups (P<0.05). Conclusion Longlu Pills combined with recombinant human follitropin has remarkable effect in treatment of polycystic ovary syndrome with infertility, and can effectively improve sex hormones in the body, and can regulate serum indicators related to the body, and also can promote ovulation function, and improve the pregnancy rate, which has a certain clinical application value.